Biocryst Pharmaceuticals (BCRX) Return on Sales (2010 - 2026)

Biocryst Pharmaceuticals' Return on Sales history runs 17 years deep, the most recent figure standing at 0.05% for Q1 2026.

• Quarterly Return on Sales fell 5.0% year-over-year to 0.05% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01% (down 1.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
• Return on Sales was 0.05% for Q1 2026 at Biocryst Pharmaceuticals, down from 3.47% in the prior quarter.
• Across five years, Return on Sales topped out at 3.47% in Q4 2025 and bottomed at 0.05% in Q1 2026.
• A 5-year average of 0.2% and a median of 0.0% in 2023 frame the typical range for Return on Sales.
• Annual changes were most pronounced in 2025 — Return on Sales soared 347 bps — and 2026, when it fell 5 bps.
• Biocryst Pharmaceuticals' Return on Sales stood at 0.01% in 2022, then increased by 27 bps to 0.01% in 2023, then surged by 69 bps to 0.0% in 2024, then jumped by 170556 bps to 3.47% in 2025, then sank by 101 bps to 0.05% in 2026.
• Business Quant data shows BCRX's Return on Sales at 0.05% in Q1 2026, 3.47% in Q4 2025, and 0.0% in Q3 2025.